title: Genetic toxicity assessment: employing the best science for human safety evaluation. Part II: Performances of the in vitro micronucleus test compared to the mouse lymphoma assay and the in vitro chromosome aberration assay.
abstract: The in vitro micronucleus test is commonly used in the early stages of pharmaceutical development as a predictive tool for the regulatory mouse lymphoma assay or in vitro chromosome aberration test. The accumulated data from this assay leads to the suggestion that it could be used as an alternative to the chromosome aberration test or the mouse lymphoma assay in the regulatory genotoxicity battery. In this paper, we present the results of the in vitro micronucleus test on L5178Y mouse lymphoma cells with 25 compounds from Servier research and have compared these results to those obtained in the genotoxicity regulatory battery. All the negative compounds were also negative in the in vitro micronucleus assay. Among the 14 positive compounds, two of them, positive in the mouse lymphoma assay, were found negative in the in vitro micronucleus test. However, this apparent discordance was likely to be due to cytotoxicity- or high concentration-related false positive responses in the mouse lymphoma assay. In addition, we confirmed that the in vitro micronucleus assay is useful for detecting aneugens, especially, when cells in metaphasis and multinucleated cells are also scored and when cells are allowed to recover after the long treatment. On this series of compounds, the in vitro micronucleus assay showed high sensitivity and possibly a better specificity than the mouse lymphoma assay. Thus, the in vitro micronucleus assay was shown to be at least as adequate as the mouse lymphoma assay or the in vitro chromosome aberration test to be used in the standard genotoxicity battery.
authors.affiliation: Servier Group, Drug Safety Assessment, 45403 Orléans-Gidy, France. elisabeth.lorge@fr.netgrs.com
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Lorge
authors.forename: Carine
authors.initials: C
authors.lastname: Lambert
authors.forename: Véronique
authors.initials: V
authors.lastname: Gervais
authors.forename: Nathalie
authors.initials: N
authors.lastname: Becourt-Lhote
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Delongeas
authors.forename: Nancy
authors.initials: N
authors.lastname: Claude
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002869:Chromosome Aberrations / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D015507:Drugs, Investigational / Q000633:toxicity*; D006801:Humans; D008223:Lymphoma / Q000235:genetics / Q000473:pathology; D051379:Mice; D015162:Micronucleus Tests / Q000379:methods*; D018675:Toxicity Tests / Q000379:methods
chemical_list: D015507:Drugs, Investigational